Home - VHIO

Novel T cell bispecific antibody shows potent anti-tumor activity in preclinical models of epidermal growth factor receptor variant III (EGFRvIII) mutant glioblastoma

Published in Molecular Cancer Therapeutics*, a journal of the American Association for Cancer Research (AACR), results of a study co-led...

Cancer Grand Challenges’ annual celebration of scientific progress: the OPTIMISTICC team story and taking on the microbiota challenge

Founded by Cancer Research UK (CRUK) and the National Cancer Institute (NIH-NCI, USA) the Cancer Grand Challenges are internationally funded...

Diagnostic tissue biopsy: informing biomarker-driven clinical decision making in advanced prostate cancer

Results of a VHIO co-led retrospective study published in JCO Precision Oncology verify the use of diagnostic archival tissue biopsies...

Published in Molecular Cancer Therapeutics*, a journal of the American Association for Cancer Research (AACR), results of a study co-led...

Novel T cell bispecific antibody shows potent anti-tumor activity in preclinical models of epidermal growth factor receptor variant III (EGFRvIII) mutant glioblastoma

Founded by Cancer Research UK (CRUK) and the National Cancer Institute (NIH-NCI, USA) the Cancer Grand Challenges are internationally funded...

Cancer Grand Challenges’ annual celebration of scientific progress: the OPTIMISTICC team story and taking on the microbiota challenge

Results of a VHIO co-led retrospective study published in JCO Precision Oncology verify the use of diagnostic archival tissue biopsies...

Diagnostic tissue biopsy: informing biomarker-driven clinical decision making in advanced prostate cancer

Latest News

Published in the flagship journal of the European Society for Medical Oncology, Annals of Oncology, renowned leaders in the field…

8 August 2022

ESMO’s updated Clinical Practice Guideline: leading experts set out consensus recommendations for the diagnosis, treatment, and follow-up of oesophageal cancer

Published in the flagship journal of the European Society for Medical Oncology, Annals of Oncology, renowned leaders in the field…

Published in Molecular Cancer Therapeutics*, a journal of the American Association for Cancer Research (AACR), results of a study co-led…

2 August 2022

Novel T cell bispecific antibody shows potent anti-tumor activity in preclinical models of epidermal growth factor receptor variant III (EGFRvIII) mutant glioblastoma

Published in Molecular Cancer Therapeutics*, a journal of the American Association for Cancer Research (AACR), results of a study co-led…

VIEW MORE NEWS

Research Programs

PRECLINICAL & TRANSLATIONAL RESEARCH

Cellular Plasticity and Cancer Group

Our group focuses on the interplay between cellular plasticity, stem cells and cancer. Cellular plasticity is recognized today as a critical feature of cancer cells that enables them to transit between different cellular states, including reversible transitions.

PRECLINICAL & TRANSLATIONAL RESEARCH

Growth Factors Group

We focus our research on mechanisms of resistance to targeted therapies and most importantly, how to overcome it by showing that breast cancers resistant to T-DM1, an antibody-drug conjugate ADC)- can be efficiently treated with the second generation ADC SYD985 (Nadal-Serrano et al.).

CORE TECHNOLOGIES

Cancer Genomics Group

VHIO’s Cancer Genomics Group serves as a Core Technology laboratory. We are also dedicated to translational research as well as the development of novel genomic tests.

PRINCIPAL RESEARCHERS

César Serrano

Sarcoma Translational Research Group

Our group focuses on the study of sarcomas with oncogenic dependency on specific drivers of disease. Among these, gastrointestinal stromal…

María Abad

Cellular Plasticity and Cancer Group

Nuestro grupo se centra en la interacción entre las respuestas al estrés, la plasticidad celular y el cáncer. La plasticidad…

Raquel Pérez-López

Radiomics Group

Focused on applying imaging biomarkers and radiomics to cancer discovery, our efforts center on advancing precision imaging in personalized medicine…

Violeta Sierra

Experimental Therapeutics Group

Our group conducts bench-to-bedside preclinical research in breast cancer to advance insights into biomarkers of response to targeted therapies. To…

Events

Friday 9 September 22 - 12:00 PM scientific-seminars Laura Fouassier I Pleotropic functions of EGFR in cholangiocarcinoma

VIEW DETAIL

Friday 23 September 22 - 12:00 PM scientific-seminars Jose-Javier Bravo-Cordero I High-resolution intravital microscopy reveals the plastic behavior of disseminated dormant cells and their niches

VIEW DETAIL

Thursday 13 October 22 - 11:00 AM Patients Surgery and breast cancer: when, how and on which patients can it be performed?

VIEW DETAIL

Friday 14 October 22 - 12:00 PM scientific-seminars Alejo Efeyan I TBC

VIEW DETAIL